Skip to main content

Mequinol / tretinoin topical Pregnancy and Breastfeeding Warnings

Brand names: Solage

Mequinol / tretinoin topical Pregnancy Warnings

Mequinol-tretinoin topical has been assigned to pregnancy category X by the FDA. Dermal carcinogenicity studies in mice using approximately five times the maximum human exposure indicated that mequinol-tretinoin topical was not carcinogenic. However, the median time to onset of tumors decreased and the number of tumors increased with intercurrent exposure to ultraviolet radiation for up to 40 weeks. There are no controlled data in human pregnancy. Mequinol-tretinoin topical is contraindicated in pregnancy because the potential risk for treating solar lentigines clearly outweighs any benefit.

See references

Mequinol / tretinoin topical Breastfeeding Warnings

There are no data on the excretion of mequinol or tretinoin into human milk. The manufacturer recommends that caution be used when administering tretinoin topical to nursing women.

See references

See also

References for pregnancy information

  1. "Product Information. Solage (mequinol-tretinoin topical)." Westwood Squibb Pharmaceutical Corporation

References for breastfeeding information

  1. "Product Information. Solage (mequinol-tretinoin topical)." Westwood Squibb Pharmaceutical Corporation

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer